 |
|
Subclinical Thyroid Dysfunction as a Risk Factor for Cardiovascular Disease
John P. Walsh, MBBS, PhD;
Alexandra P. Bremner, PhD;
Max K. Bulsara, MSc;
Peter O’Leary, PhD;
Peter J. Leedman, MBBS, PhD;
Peter Feddema, BSc;
Valdo Michelangeli, PhD
Arch Intern Med. 2005;165:2467-2472.
ABSTRACT
| |
Background There have been few large epidemiological studies examining the association between thyroid dysfunction and cardiovascular disease. In particular, it is uncertain if subclinical hypothyroidism is a risk factor for cardiovascular disease.
Methods Serum thyrotropin and free thyroxine concentrations were measured in 2108 archived serum samples from a 1981 community health survey in Busselton, Western Australia (Busselton Health Study). In a cross-sectional study, we examined the prevalence of coronary heart disease in subjects with and without subclinical thyroid dysfunction. In a longitudinal study, we examined the risk of cardiovascular mortality and coronary heart disease events (fatal and nonfatal combined) to the end of 2001 (excluding subjects who had coronary heart disease at baseline).
Results In the cross-sectional analysis, subjects with subclinical hypothyroidism (n = 119) had a significantly higher prevalence of coronary heart disease than euthyroid subjects (n = 1906) (age- and sex-adjusted prevalence odds ratio, 1.8; 95% confidence interval, 1.0-3.1; P = .04). In the longitudinal analysis of subjects with subclinical hypothyroidism (n = 101), there were 21 cardiovascular deaths observed compared with 9.5 expected (age- and sex-adjusted hazard ratio, 1.5; 95% confidence interval, 1.0-2.4; P = .08) and 33 coronary heart disease events observed compared with 14.7 expected (age- and sex-adjusted hazard ratio, 1.7; 95% confidence interval, 1.2-2.4; P<.01). The increased risk of coronary heart disease events remained significant after further adjustment for standard cardiovascular risk factors. Subjects with subclinical hyperthyroidism (n = 39) had no adverse outcomes.
Conclusion Subclinical hypothyroidism may be an independent risk factor for coronary heart disease.
INTRODUCTION
Thyroid hormones have profound effects on the cardiovascular system,1 but there have been few large epidemiological studies examining the association between subclinical thyroid dysfunction and cardiovascular disease, and most studies have been of selected groups rather than community-based studies. Subclinical hyperthyroidism (reduced serum thyrotropin concentration and normal serum thyroxine level) is associated with an increased risk of atrial fibrillation2 and increased cardiovascular mortality among persons 60 years or older,3 but it is uncertain whether subclinical hypothyroidism (increased serum thyrotropin concentration and normal serum thyroxine level) is associated with increased cardiovascular risk. In cohort studies from the United Kingdom, there was no increase in cardiovascular risk among subjects with subclinical hypothyroidism3 or autoimmune thyroid disease.4 By contrast, a large cross-sectional study5 in Rotterdam, the Netherlands, reported an increased prevalence of myocardial infarction among women 55 years or older with subclinical hypothyroidism. In the longitudinal component of that study, however, the risk of myocardial infarction was not significantly increased. A recent consensus development conference on subclinical thyroid disease concluded that there was insufficient evidence as to whether subclinical hypothyroidism is associated with cardiovascular disease,6 as did an authoritative review.7 Because subclinical hypothyroidism is common, affecting around 4% of the general population and 10% to 15% of older persons,8 it is important to determine whether it is a risk factor for cardiovascular disease. We examined subclinical thyroid dysfunction as a risk factor for cardiovascular disease in a community-based study in Busselton, Western Australia (Busselton Health Study).
METHODS
The Busselton Health Study (available at: http://bsn.uwa.edu.au) includes a series of cross-sectional health surveys of adults on the electoral roll of Busselton, a rural town with a predominantly white population. Registration to vote is compulsory in Australia. Detailed descriptions of the surveys have been published previously.9 We used data from the 1981 community health survey, in which the response rate was 64%, comprising 3447 subjects. Briefly, subjects completed a health and lifestyle questionnaire, underwent electrocardiography, and had measurements of height, weight, and blood pressure. The questionnaire included items on smoking, diabetes mellitus, treatment for hypertension, and exercise, and a single question regarding history of thyroid disease or goiter (yes or no). The presence of coronary heart disease at baseline was determined by the Rose questionnaire for angina and myocardial infarction, the electrocardiogram results, and a self-reported confirmation of heart disease diagnosed by a physician.10 Venous blood was collected in the fasting state for cholesterol and triglyceride measurement, and another specimen was collected for glucose measurement 2 hours after an oral 75-g glucose load.
Archived serum samples that had been stored at –70°C were available for 2108 participants in the 1981 survey, who formed the cohort. Samples had been securely stored in airtight polypropylene tubes, which were filled to capacity and had not been thawed during storage. Although the stability of free thyroxine concentrations in long-term storage has not been formally demonstrated, the stability of other analytes, including thyrotropin, antibodies, and steroid hormones, under such conditions has been shown.11 The proportion of men was higher among subjects for whom serum samples were available compared with those for whom serum samples were not available (50% vs 40%, P<.001), but within each sex group, the age and prevalence of previously diagnosed thyroid disease did not differ significantly between subjects with and without available serum samples. Serum thyrotropin, free thyroxine, thyroid peroxidase antibody, and thyroglobulin antibody concentrations were measured using an Immulite 2000 chemiluminescent analyzer (Diagnostic Products Corporation, Los Angeles, Calif) in 2001. For the thyrotropin assay, functional sensitivity was 0.02 mIU/L. Interassay imprecision (expressed as coefficient of variation) for each analyte was as follows: thyrotropin, 7.6%; free thyroxine, 9.6%; thyroid peroxidase antibodies, 7.2%; and thyroglobulin antibodies, 8.5%. Reference ranges (based on 95% confidence intervals [CIs] after excluding gross outliers and subjects with self-reported thyroid disease or goiter) were as follows: thyrotropin, 0.4 to 4.0 mIU/L; free thyroxine, 0.7 to 1.8 ng/dL (9-23 pmol/L); thyroid peroxidase antibodies, less than 35 kIU/L; and thyroglobulin antibodies, less than 55 kIU/L. Euthyroidism was defined as a serum thyrotropin level of 0.4 to 4.0 mIU/L (regardless of free thyroxine concentration), subclinical hyperthyroidism as a thyrotropin level less than 0.4 mIU/L with normal free thyroxine, and subclinical hypothyroidism as a thyrotropin level greater than 4.0 mIU/L with normal free thyroxine.6 The subclinical hyperthyroid group was further divided into subjects with a thyrotropin level less than 0.1 mIU/L and those with a thyrotropin level between 0.1 and less than 0.4 mIU/L. The subclinical hypothyroid group was further divided into subjects with a serum thyrotropin level of 10.0 mIU/L or less and those with a thyrotropin level greater than 10.0 mIU/L. Positive thyroid antibodies was defined as an increased concentration of thyroid peroxidase antibodies or thyroglobulin antibodies.
Baseline characteristics of the study subjects in each category of thyroid dysfunction were compared with those of euthyroid subjects using linear and logistic regression models, and multivariate models were used to determine the significance of differences between thyroid categories after adjustment for age and sex. Thyrotropin and triglyceride values were log transformed for analysis. In the cross-sectional analysis, logistic regression was used to assess the association of thyroid dysfunction with the presence of coronary heart disease. Prevalence odds ratios (ORs) and 95% CIs were calculated for the categories of thyroid dysfunction. Results were adjusted for age and sex, as well as for self-reported history of thyroid disease or goiter. The following cardiovascular risk factors were included as covariates in the statistical model: diabetes mellitus (defined as a history of diabetes mellitus, treatment for diabetes mellitus, or a glucose level >200 mg/dL [>11.1 mmol/L] 2 hours after the glucose load), body mass index, cholesterol, triglycerides, exercise (number of days per week), mean arterial blood pressure, treatment for hypertension, and smoking status (never smoked, ex-smoker, current smoker of <15 cigarettes daily, current smoker of  15 cigarettes daily, or pipe or cigar smoker).
In the longitudinal analysis, morbidity and mortality outcomes up to December 31, 2001, were obtained by record linkage to the Registrar General’s list of deaths in Western Australia and the statewide Hospital Morbidity Data System, which records all admissions to public and private hospitals in Western Australia.12 Vital status at December 31, 2001, was ascertained for 95% of the cohort. The survival times for the remaining 5% were censored at the last time they were known to be alive. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes13 were used for events up to June 30, 1999, and ICD-10 codes were used for subsequent events. Cardiovascular mortality was defined as death from cardiovascular disease (ICD-9-CM codes 390-459). Coronary heart disease events were defined as death from coronary heart disease or hospital admission with a diagnosis of coronary heart disease (ICD-9-CM codes 410-414). A Cox proportional hazards regression model was used to analyze the association between thyroid dysfunction and the time from the 1981 survey until the first event. Hazard ratios and 95% CIs were calculated for the categories of thyroid dysfunction after adjustment for age and sex (by including these as covariates in the statistical model) and after further adjustment for the covariates listed at the end of the previous paragraph.
In the Whickham Survey, a serum thyrotropin level greater than 2.0 mIU/L at baseline was associated with an increased risk of subsequent hypothyroidism,14 and some authorities suggest that the upper limit of the thyrotropin reference range should be lowered from approximately 4 to 2.5 mIU/L.15 We therefore examined whether serum thyrotropin in the upper reference range (2.0-4.0 mIU/L) was associated with cardiovascular end points in the cross-sectional and longitudinal analyses, using subjects with a serum thyrotropin level of 0.4 to 2.0 mIU/L as the comparator group.
Statistical analyses were performed using S-PLUS 2000 (Insightful Corporation, Seattle, Wash). Significance was set at P<.05. The study was approved by the Royal Perth Hospital Ethics Committee.
RESULTS
The 2108 study subjects comprised 1063 men and 1045 women, with a mean age of 50 years (age range, 17-89 years). The baseline characteristics of the study subjects are given in Table 1. The prevalence of subclinical hyperthyroidism was 1.8%, and that of subclinical hypothyroidism was 5.6%. Serum cholesterol was higher in subjects with subclinical hypothyroidism than in euthyroid subjects (mean ± SD, 244 ± 50 mg/dL [6.3 ± 1.3 mmol/L] vs 224 ± 46 mg/dL [5.8 ± 1.2 mmol/L]; P<.001), but the difference was not significant after adjustment for age and sex (P = .06). Serum triglycerides were also higher in subjects with subclinical hypothyroidism than in euthyroid subjects (mean ± SD, 151 ± 124 mg/dL [1.7 ± 1.4 mmol/L] vs 124 ± 89 mg/dL [1.4 ± 1.0 mmol/L]; P = .02), but the difference was not significant after adjustment for age and sex (P = .11).
|
|
|
|
Table 1. Baseline Characteristics of the Study Subjects*
|
|
|
CROSS-SECTIONAL ANALYSIS
In the cross-sectional analysis, the prevalence OR for coronary heart disease was significantly increased (after adjustment for age and sex) in subjects with subclinical hypothyroidism compared with euthyroid subjects (OR, 1.8; 95% CI, 1.0-3.1; P = .04) (Table 2). The association remained significant after further adjustment for standard cardiovascular risk factors and self-reported thyroid disease or goiter (OR, 2.2; 95% CI, 1.2-4.0; P = .01). When subjects with subclinical hypothyroidism were divided into those with a serum thyrotropin level of 10.0 mIU/L or less and those with a serum thyrotropin level greater than 10.0 mIU/L, the association with coronary heart disease was significant only in the latter subgroup. No significant association was found between subclinical hyperthyroidism and coronary heart disease.
|
|
|
|
Table 2. Prevalence Odds Ratios for Coronary Heart Disease in the Cross-sectional Analysis of All Subjects*
|
|
|
The analysis was repeated after excluding subjects with a history of thyroid disease or goiter at baseline (n = 75). In this analysis, the ORs for coronary heart disease in subjects with subclinical hypothyroidism (n = 105) were 1.7 (95% CI, 0.9-3.0; P = .09) after adjustment for age and sex and 2.0 (95% CI, 1.1-3.8; P = .03) after adjustment for multiple covariates.
The prevalence of coronary heart disease was not significantly increased among subjects with a serum thyrotropin level in the upper reference range (>2.0 mIU/L) compared with those with a serum thyrotropin level of 0.4 to 2.0 mIU/L. It also did not differ significantly between subjects with positive thyroid antibodies and antibody-negative subjects (data not shown).
LONGITUDINAL ANALYSIS
In 1926 subjects who were free of coronary heart disease at baseline cardiovascular mortality was not significantly increased in any of the groups with thyroid dysfunction (ie, 1890 subjects who were categorized as having subclinical hyperthyroidism, euthyroidism, or subclinical hypothyroidism) (Table 3). In subjects with subclinical hypothyroidism at baseline, the hazard ratio (HR) for death from cardiovascular disease (after adjustment for age and sex) was 1.5 (95% CI, 1.0-2.4; P = .08). The risk of coronary heart disease events (fatal and nonfatal combined) was significantly increased in subjects with subclinical hypothyroidism after adjustment for age and sex (HR, 1.7; 95% CI, 1.2-2.4; P<.01) and after further adjustment for cardiovascular risk factors and self-reported thyroid disease or goiter (HR, 1.8; 95% CI, 1.2-2.7; P<.01) (Table 4 and the Figure). The increased risk associated with subclinical hypothyroidism was apparent in subjects with a serum thyrotropin level of 10.0 mIU/L or less and in those with a serum thyrotropin level greater than 10.0 mIU/L. There was no significant increase in risk of coronary heart disease events in subjects with subclinical hyperthyroidism as a group or in the subgroups with a serum thyrotropin level less than 0.1 mIU/L or a serum thyrotropin level between 0.1 and 0.4 mIU/L.
|
|
|
|
Table 3. Hazard Ratios for Cardiovascular Mortality in the Longitudinal Analysis of Subjects Free of Coronary Heart Disease at Baseline*
|
|
|
|
|
|
|
Table 4. Hazard Ratios for Coronary Heart Disease Events (Fatal and Nonfatal) in the Longitudinal Analysis of Subjects Free of Coronary Heart Disease at Baseline*
|
|
|
|
|
|
|
Figure. Kaplan-Meier plots for survival free of coronary heart disease events (fatal or nonfatal) in subjects without coronary heart disease at baseline.
|
|
|
When subjects with self-reported thyroid disease or goiter at baseline were excluded from the analysis, subjects with subclinical hypothyroidism (n = 90) still had a significantly increased risk of coronary heart disease events (28 events observed and 13 expected; HR after adjustment for age and sex, 1.6; 95% CI, 1.1-2.3; P = .02; and HR after adjustment for multiple covariates, 1.7; 95% CI, 1.1-2.5; P = .02).
The risk of coronary heart disease events in euthyroid subjects with serum thyrotropin levels in the upper reference range (>2.0 mIU/L) (n = 432) did not differ from that in those with serum thyrotropin levels in the lower reference range ( 2.0 mIU/L) (n = 1474) after adjustment for age and sex (age- and sex-adjusted HR, 0.9; 95% CI, 0.7-1.2; P = .70). After adjustment for age and sex, positive thyroid antibodies at baseline were not associated with increased cardiovascular mortality (HR, 1.0; 95% CI, 0.7-1.4; P = .97) or increased risk of coronary heart disease events (HR, 1.3; 95% CI, 0.8-2.0; P = .30) compared with antibody-negative subjects. Among subjects with subclinical hypothyroidism, the risk of coronary heart disease events did not differ significantly between subjects with positive thyroid antibodies (age- and sex-adjusted HR, 0.6; 95% CI, 0.3-1.2; P = .18) compared with antibody-negative subjects.
COMMENT
In this community-based study, subclinical hypothyroidism was an independent predictor of coronary heart disease (after adjustment for age and sex) in the cross-sectional and longitudinal analyses. These results are in agreement with previous cross-sectional studies showing an association between subclinical hypothyroidism and coronary heart disease in selected groups, namely, women 55 years or older,5 Japanese atomic bomb survivors,16 nursing home residents,17 men younger than 50 years,18 and older community-dwelling subjects.19 Our findings go beyond these studies, first, because we studied an unselected population and, second, because the increased cardiac risk was apparent in the cross-sectional and longitudinal components of our study. To our knowledge, this is the first cohort study to demonstrate an association between subclinical hypothyroidism and coronary heart disease. It is generally recognized that cohort studies provide stronger evidence than cross-sectional studies for a causal association.20
Our results differ from those of the longitudinal component of the Rotterdam Study5 and the cohort study by Parle et al,3 in which subclinical hypothyroidism was not associated with a significant increase in cardiovascular risk. This is probably explained by the shorter follow-up in those studies (4.6 years in the Rotterdam Study and 10 years in the study by Parle et al, compared with 20 years in our study), because in our Kaplan-Meier plots, the divergence of the disease-free survival curves is most obvious from 10 years onward. Our results appear to differ from those of a 20-year cohort study4 that reported no association between autoimmune thyroid disease and coronary heart disease. In that study, however, subjects with subclinical hypothyroidism were combined with antibody-positive, euthyroid subjects for analysis and not analyzed as a separate group. Our findings also differ from a cohort study16 from Japan, in which subclinical hypothyroidism was associated with increased all-cause mortality. In that study, however, the excess mortality was limited to years 3 through 6 of follow-up and was observed only in men, making the data difficult to interpret. In addition, that cohort was highly selected (atomic bomb survivors). Those results and ours differ from a recent cohort study21 of subjects aged 85 years at baseline in which subclinical hypothyroidism was associated with greater longevity. The reason for this is not clear, but it may be that subclinical hypothyroidism has different implications in very old subjects compared with the general population.
In contrast to the study by Parle et al,3 we found no evidence of increased cardiovascular risk associated with subclinical hyperthyroidism. This may be because our cohort was younger, with a lower prevalence of subclinical hyperthyroidism and fewer cardiovascular events, than the subjects in the study by Parle et al, who were 60 years or older at baseline.
The strengths of our study include a large sample size, its community-based design (avoiding biases present in studies of smaller selected groups), and the comprehensive follow-up, with only 5% of subjects being lost to follow-up during a 20-year period. Only one previous cohort study (the Whickham Survey14) has examined the association between thyroid dysfunction and cardiovascular disease in an unselected community-based sample.
Our study also has weaknesses. First, although participants in the 1981 survey were asked if they had a history of thyroid disease or goiter, details of diagnosis and treatment were not recorded. It is therefore possible that some subjects in the subclinical hypothyroid group had inadequately treated overt hypothyroidism or over-treated hyperthyroidism. However, excluding subjects with self-reported thyroid disease or goiter at baseline made little difference in the results, suggesting that this is not a major confounder. Second, thyroid function was measured only at baseline, and we have no data on progression or treatment of thyroid dysfunction among the members of the cohort. The natural history of subclinical hypothyroidism is variable; thyroid function normalizes spontaneously in some subjects, whereas it progresses to overt hypothyroidism in others.14, 22-23 It is therefore possible that the increase in cardiac events observed in the subclinical hypothyroid group arose not because of subclinical hypothyroidism per se but because of progression to overt hypothyroidism, which is associated with atherosclerosis.24 This, however, would not explain the association between subclinical hypothyroidism and coronary heart disease in the cross-sectional analysis, and the consistency between the cross-sectional and longitudinal components of our study constitutes strong evidence that subclinical hypothyroidism is indeed a risk factor for coronary heart disease. Third, ascertainment of cardiovascular events was based on population-based linkage of health records rather than on clinical follow-up of the cohort; however, previous findings have shown that diagnostic codes obtained using these methods are reliable.15 Fourth, although we adjusted for serum total cholesterol concentrations, high-density lipoprotein and low-density lipoprotein cholesterol concentrations were not available and could not be included in the analysis.
A causal relationship between subclinical hypothyroidism and cardiovascular disease is biologically plausible. Subclinical hypothyroidism is associated with hypercholesterolemia (although the evidence for this is convincing only for subjects with a serum thyrotropin level >10.0 mIU/L6), left ventricular diastolic dysfunction that is reversible with thyroxine therapy,25-27 and impaired endothelium-dependent vasodilatation, a marker of atherosclerosis.26, 28-29
Our study is observational, and it does not necessarily follow that treatment of subclinical hypothyroidism will reduce the risk of cardiovascular disease. To demonstrate such a benefit would require a large clinical trial with a long follow-up period. Until such a trial is conducted, evidence-based management of subclinical hypothyroidism will be based on epidemiological studies such as this and on clinical trials with surrogate cardiovascular end points.
AUTHOR INFORMATION
Correspondence: John P. Walsh, MBBS, PhD, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia (john.walsh{at}health.wa.gov.au).
Accepted for Publication: July 5, 2005.
Author Contributions: Dr Walsh had full access to all the data in this study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: Mr Feddema and Dr Michelangeli are employees of BioMediq DPC, a subsidiary of Diagnostic Products Corporation, manufacturer of the autoanalyzer and immunoassay kits used in this study.
Funding/Support: This study was supported by a research grant from Merck Sharp & Dohme Australia, Granville, New South Wales.
Role of the Sponsor: The sponsor had no role in the design and conduct of this study or in the collection, management, analysis, or interpretation of the data. The sponsor was invited to review the manuscript before submission, but approval was not required.
Previous Presentation: This study was presented at the 76th Annual Meeting of the American Thyroid Association; October 1, 2004; Vancouver, British Columbia.
Acknowledgment: We thank the Busselton Population Medical Research Foundation for permission to access the survey data and stored serum samples, Davina Whittall, BSc, for help in accessing serum samples, Helen Bartholomew, BSc, for data extraction and advice, and Matthew Knuiman, PhD, for advice.
Author Affiliations: Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital (Dr Walsh), Genomics Directorate, Department of Health (Dr O’Leary), and Department of Endocrinology and Diabetes, Royal Perth Hospital, and Laboratory for Cancer Medicine, UWA Centre for Medical Research, Faculty of Medicine and Dentistry of The University of Western Australia (Dr Leedman), Perth; School of Medicine and Pharmacology (Drs Walsh and Leedman), School of Population Health (Dr Bremner and Mr Bulsara), and School of Women’s and Infants’ Health (Dr O’Leary), The University of Western Australia, Crawley; and BioMediq DPC, Doncaster, Victoria (Mr Feddema and Dr Michelangeli); Australia.
REFERENCES
| |
1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-509.
FREE FULL TEXT
2. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252.
FREE FULL TEXT
3. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358:861-865.
FULL TEXT
|
ISI
| PUBMED
4. Vanderpump MP, Tunbridge WM, French JM, et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid. 1996;6:155-160.
ISI
| PUBMED
5. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270-278.
FREE FULL TEXT
6. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238.
FREE FULL TEXT
7. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:128-141.
FREE FULL TEXT
8. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
FREE FULL TEXT
9. Knuiman MW, Jamrozik K, Welborn TA, Bulsara MK, Divitini ML, Whittall DE. Age and secular trends in risk factors for cardiovascular disease in Busselton. Aust J Public Health. 1995;19:375-382.
ISI
| PUBMED
10. Welborn TA, Cumpston GN, Cullen KJ, Curnow DH, McCall MG, Stenhouse NS. The prevalence of coronary heart disease and associated factors in an Australian rural community. Am J Epidemiol. 1969;89:521-536.
FREE FULL TEXT
11. Jellum E, Andersen A, Lund-Larsen P, Theodorsen L, Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995;103(suppl 3):85-88.
PUBMED
12. Holman CDJ, Bass AJ, Rouse IL, Hobbs MST. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health. 1999;23:453-459.
ISI
| PUBMED
13. International Classification of Diseases, Ninth Revision, Clinical Modification. Ann Arbor, Mich: Commission on Professional & Hospital Activities; 1986.
14. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43:55-68.
PUBMED
15. Baloch Z, Carayon P, Conte-Devolx B, et al, Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3-126.
FULL TEXT
|
ISI
| PUBMED
16. Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab. 2004;89:3365-3370.
FREE FULL TEXT
17. Mya MM, Aronow WS. Increased prevalence of peripheral arterial disease in older men and women with subclinical hypothyroidism. J Gerontol A Biol Sci Med Sci. 2003;58:68-69.
ISI
| PUBMED
18. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf). 2004;61:232-238.
FULL TEXT
| PUBMED
19. Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgartner RN, Garry PJ. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid. 2003;13:595-600.
FULL TEXT
|
ISI
| PUBMED
20. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet. 2002;359:341-345.
FULL TEXT
|
ISI
| PUBMED
21. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591-2599.
FREE FULL TEXT
22. Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab. 2004;89:4890-4897.
FREE FULL TEXT
23. Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab. 2002;87:3221-3226.
FREE FULL TEXT
24. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003;88:2438-2444.
FREE FULL TEXT
25. Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86:1110-1115.
FREE FULL TEXT
26. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137:904-914.
FREE FULL TEXT
27. Brenta G, Mutti LA, Schnitman M, Fretes O, Perrone A, Matute ML. Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy. Am J Cardiol. 2003;91:1327-1330.
FULL TEXT
|
ISI
| PUBMED
28. Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003;88:3731-3737.
FREE FULL TEXT
29. Cikim AS, Oflaz H, Ozbey N, et al. Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid. 2004;14:605-609.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Subclinical Hypothyroidism and Cardiovascular Disease
Lawrence M. Crapo
Arch Intern Med. 2005;165(21):2451-2452.
EXTRACT
| FULL TEXT
Subclinical Hypothyroidism and the Risk of Heart Failure, Other Cardiovascular Events, and Death
Nicolas Rodondi, Anne B. Newman, Eric Vittinghoff, Nathalie de Rekeneire, Suzanne Satterfield, Tamara B. Harris, and Douglas C. Bauer
Arch Intern Med. 2005;165(21):2460-2466.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Endothelial-mediated coronary flow reserve in patients with mild thyroid hormone deficiency
Biondi et al.
Eur J Endocrinol 2009;161:323-329.
ABSTRACT
| FULL TEXT
Elevated serum creatine kinase predicts first-ever myocardial infarction: a 12-year population-based cohort study in Japan, the Suita study
Watanabe et al.
Int J Epidemiol 2009;0:dyp212v1-dyp212.
ABSTRACT
| FULL TEXT
Euthyroid Hyperthyrotropinemia in Children Born after in Vitro Fertilization
Sakka et al.
J. Clin. Endocrinol. Metab. 2009;94:1338-1341.
ABSTRACT
| FULL TEXT
Subclinical Hyperthyroidism: Considerations in Defining the Lower Limit of the Thyrotropin Reference Interval
Goichot et al.
Clin. Chem. 2009;55:420-424.
ABSTRACT
| FULL TEXT
Increased reverse triiodothyronine is associated with shorter survival in independently-living elderly: the Alsanut study
Forestier et al.
Eur J Endocrinol 2009;160:207-214.
ABSTRACT
| FULL TEXT
Subclinical Thyroid Dysfunction, Cardiac Function, and the Risk of Heart Failure: The Cardiovascular Health Study
Rodondi et al.
J Am Coll Cardiol 2008;52:1152-1159.
ABSTRACT
| FULL TEXT
Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies
Haentjens et al.
Eur J Endocrinol 2008;159:329-341.
ABSTRACT
| FULL TEXT
Should we treat all subjects with subclinical thyroid disease the same way?
Biondi
Eur J Endocrinol 2008;159:343-345.
FULL TEXT
Prevalence of Subclinical Hypothyroidism in Patients with Chronic Kidney Disease
Chonchol et al.
CJASN 2008;3:1296-1300.
ABSTRACT
| FULL TEXT
The Influence of Age on the Relationship between Subclinical Hypothyroidism and Ischemic Heart Disease: A Metaanalysis
Razvi et al.
J. Clin. Endocrinol. Metab. 2008;93:2998-3007.
ABSTRACT
| FULL TEXT
Thyroid Function and the Risk of Alzheimer Disease: The Framingham Study
Tan et al.
Arch Intern Med 2008;168:1514-1520.
ABSTRACT
| FULL TEXT
Meta-analysis: Subclinical Thyroid Dysfunction and the Risk for Coronary Heart Disease and Mortality
Ochs et al.
ANN INTERN MED 2008;148:832-845.
ABSTRACT
| FULL TEXT
Retinol Binding Protein-4 Elevation Is Associated with Serum Thyroid-Stimulating Hormone Level Independently of Obesity in Elderly Subjects with Normal Glucose Tolerance
Choi et al.
J. Clin. Endocrinol. Metab. 2008;93:2313-2318.
ABSTRACT
| FULL TEXT
Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism
Liu et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H2137-H2143.
ABSTRACT
| FULL TEXT
Thyrotropin Levels and Risk of Fatal Coronary Heart Disease: The HUNT Study
Asvold et al.
Arch Intern Med 2008;168:855-860.
ABSTRACT
| FULL TEXT
Thyroid Function and Lipid Subparticle Sizes in Patients with Short-Term Hypothyroidism and a Population-Based Cohort
Pearce et al.
J. Clin. Endocrinol. Metab. 2008;93:888-894.
ABSTRACT
| FULL TEXT
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi and Cooper
Endocr. Rev. 2008;29:76-131.
ABSTRACT
| FULL TEXT
Altered Platelet Plug Formation in Hyperthyroidism and Hypothyroidism
Homoncik et al.
J. Clin. Endocrinol. Metab. 2007;92:3006-3012.
ABSTRACT
| FULL TEXT
Association Between Increased Mortality and Mild Thyroid Dysfunction in Cardiac Patients
Iervasi et al.
Arch Intern Med 2007;167:1526-1532.
ABSTRACT
| FULL TEXT
Serum Thyrotropin Measurements in the Community: Five-Year Follow-up in a Large Network of Primary Care Physicians
Meyerovitch et al.
Arch Intern Med 2007;167:1533-1538.
ABSTRACT
| FULL TEXT
The Association of Thyroid Dysfunction with All-Cause and Circulatory Mortality: Is There a Causal Relationship?
Volzke et al.
J. Clin. Endocrinol. Metab. 2007;92:2421-2429.
ABSTRACT
| FULL TEXT
Hyperthyroidism and Mortality
Volzke
J Am Coll Cardiol 2007;49:2228-2229.
FULL TEXT
Association Between Serum Free Thyroxine Concentration and Atrial Fibrillation
Gammage et al.
Arch Intern Med 2007;167:928-934.
ABSTRACT
| FULL TEXT
The Beneficial Effect of L-Thyroxine on Cardiovascular Risk Factors, Endothelial Function, and Quality of Life in Subclinical Hypothyroidism: Randomized, Crossover Trial
Razvi et al.
J. Clin. Endocrinol. Metab. 2007;92:1715-1723.
ABSTRACT
| FULL TEXT
Effect of Levo-Thyroxine Replacement on Non-High-Density Lipoprotein Cholesterol in Hypothyroid Patients
Ito et al.
J. Clin. Endocrinol. Metab. 2007;92:608-611.
ABSTRACT
| FULL TEXT
Approach to the Patient with Subclinical Hyperthyroidism
Cooper
J. Clin. Endocrinol. Metab. 2007;92:3-9.
ABSTRACT
| FULL TEXT
Prevalence of Subclinical Thyroid Dysfunction and Its Relation to Socioeconomic Deprivation in the Elderly: A Community-Based Cross-Sectional Survey
Wilson et al.
J. Clin. Endocrinol. Metab. 2006;91:4809-4816.
ABSTRACT
| FULL TEXT
Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-stimulating hormone: effect of adipocyte differentiation and anatomic depot
Antunes et al.
Am. J. Physiol. Endocrinol. Metab. 2006;290:E1140-E1144.
ABSTRACT
| FULL TEXT
Erectile dysfunction and incidence of cardiovascular disease.
Mascitelli and Pezzetta
JAMA 2006;295:1998-1999.
FULL TEXT
Other articles noted
Evid. Based Med. 2006;11:63-64.
FULL TEXT
Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults
Cappola et al.
JAMA 2006;295:1033-1041.
ABSTRACT
| FULL TEXT
Subclinical Hypothyroidism and Cardiovascular Disease
Journal Watch Cardiology 2006;2006:8-8.
FULL TEXT
Subclinical Hypothyroidism and Cardiovascular Disease
JWatch General 2006;2006:1-1.
FULL TEXT
Subclinical Hypothyroidism and Cardiovascular Disease
Crapo
Arch Intern Med 2005;165:2451-2452.
FULL TEXT
|
